Dapagliflozin in Patients with Chronic Kidney Disease

In this trial, patients with CKD (with or without type 2 diabetes) were randomly assigned to receive dapagliflozin or placebo. The primary composite outcome — a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes — was less f...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 383; číslo 15; s. 1436 - 1446
Hlavní autori:	Heerspink, Hiddo J.L, Stefánsson, Bergur V, Correa-Rotter, Ricardo, Chertow, Glenn M, Greene, Tom, Hou, Fan-Fan, Mann, Johannes F.E, McMurray, John J.V, Lindberg, Magnus, Rossing, Peter, Sjöström, C. David, Toto, Roberto D, Langkilde, Anna-Maria, Wheeler, David C
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 08.10.2020
Predmet:	Aged Albumin Antidiabetics Benzhydryl Compounds - adverse effects Benzhydryl Compounds - pharmacology Benzhydryl Compounds - therapeutic use Cardiovascular Diseases - etiology Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Clinical trials Congestive heart failure Creatinine Death Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic Nephropathies - drug therapy End-stage renal disease Female Glomerular filtration rate Glomerular Filtration Rate - drug effects Glucose Glucosides - adverse effects Glucosides - pharmacology Glucosides - therapeutic use Humans Kaplan-Meier Estimate Kidney diseases Kidney Failure, Chronic - mortality Laboratories Male Middle Aged Population Regression Analysis Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - drug therapy Sodium-Glucose Transporter 2 Inhibitors - adverse effects Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Statistical analysis
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	In this trial, patients with CKD (with or without type 2 diabetes) were randomly assigned to receive dapagliflozin or placebo. The primary composite outcome — a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes — was less frequent with dapagliflozin.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2024816